Publications by authors named "D Lehmann"

Article Synopsis
  • The study focuses on how immobilizing GaPt liquid metal alloy droplets on specially designed supports can enhance catalytic performance by preventing droplet merging and losing active surface area.
  • Researchers used supraparticle (SP) supports with varying pore sizes to investigate how these sizes influence the stability of GaPt droplets during propane dehydrogenation reactions.
  • Results showed that larger pore sizes led to better stability of the GaPt droplets, reducing deactivation rates and confirming successful immobilization without changes before and after the reaction, highlighting the importance of pore size in catalyst support design.*
View Article and Find Full Text PDF

Unlabelled: Individuals with chronic spinal cord injury (SCI) face elevated risks of cardiometabolic diseases, including cardiovascular disease and type 2 diabetes, due to factors like physical inactivity, neurogenic obesity, and disrupted glucose and insulin regulation. We conducted a prospective intervention cohort study involving 20 individuals with SCI (aged 28-60) with neurologic injuries at levels C4-T10 and ASIA scale grades A-D, lasting over a year. Our study assessed the impact of a therapeutic lifestyle intervention (TLI) based on the Diabetes Prevention Program (DPP) and its maintenance phase.

View Article and Find Full Text PDF

Introduction: This study is a prospective comparative case series analysing the differential impacts of a therapeutic lifestyle intervention (TLI) on individuals with spinal cord injury (SCI) and their caregivers. The primary objective was to assess changes across several health metrics predictive of cardio metabolic disease (CMD), fitness, and quality of life, in dyadic partners and between 2 separate cases.

Case Presentation: SCI participants and their respective caregivers, forming 10 dyads, were included in the study.

View Article and Find Full Text PDF

Background: In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.

Methods And Findings: In 2 sequential parallel, open-label, randomised controlled trials (the PREVIX trials), eligible infants were first allocated 1:1:1 at age 28 to 38 days to standard or mixed PCV schedules, then at age 12 months to PCV13 (13-valent pneumococcal conjugate vaccine, +P) or PHiD-CV10 (10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine, +S) (1:1).

View Article and Find Full Text PDF